3 months ago
ARGX
AnalystsJoon LeeJoon Lee's Stock Forecasts
AnalystsJoon Lee
Sectors:
Industries:
Analyst Ranking
Top 7%
#289 out of 4587 analysts
Average Return
+25.52%
Win Rate
47%35 out of 75
Risk vs Reward
Poor
Good
Joon Lee's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Viking Therapeutics IncVKTX | +516.38% | $10.87 | $67.00 | 2023-10-01 - 2024-05-17 | Strong Buy |
Intellia Therapeutics IncNTLA | +418.87% | $25.44 | $132.00 | 2020-10-26 - 2021-10-26 | Strong Buy |
Viking Therapeutics IncVKTX | +414.75% | $15.93 | $82.00 | 2023-03-28 - 2024-03-28 | Strong Buy |
Viking Therapeutics IncVKTX | +344.30% | $15.08 | $67.00 | 2023-12-03 - 2024-05-17 | Strong Buy |
Taysha Gene Therapies IncTSHA | +341.54% | $0.65 | $2.87 | 2023-03-28 - 2024-03-28 | Strong Buy |
Joon Lee Analyst Color
Get additional color on Joon Lee's coverage of popular stocks
3 months ago
VKTX
3 months ago
CORT
5 months ago
EDIT
6 months ago
CORT
9 months ago
TSHA
9 months ago
SAGE
a year ago
VKTX
Joon Lee's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Praxis Precision Medicines IncPRAX | 3 | Strong Buy | $150.00 | +230.47% | Maintains | 4 days ago |
Viking Therapeutics IncVKTX | 6 | Strong Buy | $120.00 | +79.10% | Reiterates | 4 days ago |
Adverum Biotechnologies IncADVM | 5 | Strong Buy | $60.00 | +646.27% | Maintains | 5 days ago |
Corcept Therapeutics IncCORT | 4 | Strong Buy | $44.00 | +56.64% | Maintains | 18 days ago |
Sage Therapeutics IncSAGE | 5 | Hold | $18.00 | +53.85% | Maintains | 24 days ago |
Marinus Pharmaceuticals IncMRNS | 6 | Strong Buy | $10.00 | +651.88% | Maintains | a month ago |
Wave Life Sciences LtdWVE | 2 | Strong Buy | $17.00 | +171.57% | Reiterates | 2 months ago |
Axsome Therapeutics IncAXSM | 2 | Strong Buy | $150.00 | +95.98% | Maintains | 2 months ago |
Arvinas IncARVN | 5 | Strong Buy | $65.00 | +98.90% | Reiterates | 2 months ago |
Jazz Pharmaceuticals PLCJAZZ | 2 | Strong Buy | $200.00 | +83.50% | Reiterates | 2 months ago |
Argenx SeARGX | 8 | Strong Buy | $440.00 | +20.28% | Maintains | 3 months ago |
Cormedix IncCRMD | 4 | Strong Buy | $14.00 | +173.44% | Maintains | 4 months ago |
Editas Medicine IncEDIT | 5 | Strong Buy | $20.00 | +255.87% | Maintains | 5 months ago |
Crispr Therapeutics AgCRSP | 3 | Strong Buy | $160.00 | +184.60% | Maintains | 5 months ago |
Taysha Gene Therapies IncTSHA | 7 | Strong Buy | $5.00 | +61.81% | Maintains | 8 months ago |
Verona Pharma PLCVRNA | 3 | Strong Buy | $32.00 | +146.15% | Reiterates | a year ago |
Catalyst Pharmaceuticals IncCPRX | 5 | Strong Buy | $24.00 | +45.54% | Maintains | a year ago |
Voyager Therapeutics IncVYGR | 1 | Strong Buy | $18.00 | N/A | Initiates Coverage On | a year ago |
Concert Pharmaceuticals IncCNCE | 2 | Strong Buy | $25.00 | N/A | Maintains | 2 years ago |
Aptinyx IncAPTX | 2 | Hold | N/A | N/A | Downgrades | 2 years ago |
Cyclerion Therapeutics IncCYCN | 1 | Strong Buy | $280.00 | N/A | Initiates Coverage On | 3 years ago |
Global Blood Therapeutics IncGBT | 1 | Strong Buy | $50.00 | N/A | Upgrades | 3 years ago |
Intellia Therapeutics IncNTLA | 2 | Strong Buy | $160.00 | N/A | Maintains | 3 years ago |
Translate Bio IncTBIO1 | 2 | Hold | $360.00 | N/A | Downgrades | 3 years ago |
Anaptysbio IncANAB | 1 | Strong Buy | $34.00 | N/A | Upgrades | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.